Physician profile
Prashant Sharma
NPI 1902059314
$9,524.96
in general payments reported to CMS, 2019-2025
42 companies · $2,151 in 2025
The $2,151 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $527 · 2021: $1,443 · 2022: $1,017 · 2023: $1,089 · 2024: $1,999 · 2025: $2,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,013 · Travel and Lodging: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,013.15 |
| Travel and Lodging | $225.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,258.44 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,697.72 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Boston Scientific Corporation | $660.15 | 2019-2025 | Exalt Model D, General - Therapies |
| Phathom Pharmaceuticals, INC. | $584.15 | 2024-2025 | Voquezna |
| Genzyme Corporation | $465.43 | 2023-2025 | |
| Pfizer INC. | $413.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $411.97 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $340.32 | 2019-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $299.51 | 2023-2025 | Omvoh, Zepbound |
| Medtronic, INC. | $272.74 | 2021-2025 | Endoflip, Interstim |
| Regeneron Healthcare Solutions, INC. | $226.19 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $186.25 | 2020-2023 | |
| Ironwood Pharmaceuticals, INC | $146.77 | 2019-2024 | Linzess |
| Covidien LP | $144.41 | 2019 | |
| Endogastric Solutions, INC | $125.00 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.